Cooperation agreements sought in cancer and inflammation with new therapies

Short summary A French company developed new therapeutic antibodies targeting immune-receptors. They are currently seeking partners to validate proof of concept in cancer and inflammation using new in vitro or in vivo approaches. License agreement as well as research and/or technical cooperation agreements are sought.

Full description The French company is a spin-off of a very well known French research organisation created by researchers 10 years ago. They do have a lot of expertise on those therapeutic targets and generated tools to address both their physiological and pathological roles. Nowadays they are looking for partners in order to validate proof of concept in cancer and inflammation. Partners can be: companies, Contract Research Organisations (CRO) as well as academics. Several partnerships can be envisaged: license agreement, research cooperation agreement or technical cooperation agreement.

Advantages and innovations These antibodies are patented and available for collaborations.
Contact / source: NEXT EEN Widgets (europa.eu)